Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unveiling BRAF Mutations in Non-small Cell Lung Cancer: State of the Art and Future Perspectives.

Lung - 16 Sept 2026

Colombino Maria, Paliogiannis Panagiotis, Palomba Grazia, Pisano Marina, Casula Milena, Fois Alessandro Giuseppe, Zinellu Angelo, Palmieri Giuseppe

Abstract excerpt

BACKGROUND AND PURPOSE: Lung cancer is the most frequently diagnosed malignancy worldwide in recent decades, representing the leading cause of cancer-related mortality globally. Lung cancer is mainly divided into two types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC being the most common, representing about 85% of cases. NSCLC is increasingly recognized to harbor various...

Read the complete abstract on PubMed

Topics

Humans
Proto-Oncogene Proteins B-raf
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Mutation
Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Immunotherapy

Drug Resistance, Neoplasm

Source

Open in PubMed Open full text

Identifiers

PMID: 42747511
DOI: 10.1007/s00408-026-00932-9
PMCID: PMC13582093

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unveiling BRAF Mutations in Non-small Cell Lung Cancer: State of the Art and Future Perspectives.PMID 42747511Read ↗

Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Semantic proximity Read ↗

[Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Expert consensus on the diagnosis and treatment in advanced non-small cell lung cancer with BRAF mutation in China].Semantic proximity Read ↗

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.Semantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.Semantic proximity Read ↗

KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.Semantic proximity Read ↗

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.Semantic proximity Read ↗

[Research Progress of Targeted Therapy for BRAF Mutation in Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

A BRAF new world.Semantic proximity Read ↗

Pathways and targeting avenues of BRAF in non-small cell lung cancer.Semantic proximity Read ↗

Advances in anti-BRAF therapies for lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.